Genmab rises on upbeat 2025 sales forecast

Genmab A/S

12/02/2025 19:05

** U.S.-listed shares of Denmark-based drugmaker Genmab
 GMAB.CO   GMAB.O  up 1.9% to $19.24 
    ** Company, which develops cancer treatments, sees 2025
sales to be in the range of $3.3 billion to $3.7 billion,
banking on strong demand for its blood cancer treatment Darzalex
    ** Analysts were expecting revenue of $3.56 billion on
average for 2025 — LSEG
    ** Genmab partnered with Johnson & Johnson  JNJ.N  for
Darzalex   
    ** Partner JNJ reported full-year sales of Darzalex rose
20.6% to $11.67 billion in 2024
    ** Expects 2025 operating expenses to be in the range of
$2.1 billion to $2.2 billion due to ongoing late-stage studies
of cancer treatments and potential planned launches
    ** In the last 12 months, stock has fallen 31.1% 

 (Reporting by Siddhi Mahatole)
 ((Siddhiprabhanjan.mahatole@thomsonreuters.com))